Therapeutics
FAKnostics has developed a series of hydrocarbon-stapled peptides that block the FAK FAT domain.
Our peptides have demonstrated enhanced alpha helicity, permeability, binding affinity, proteolytic resistance, and pharmacokinetic properties.
​
Currently, we have several very promising anti-cancer products in in-vitro, pre-clinical, and pre-IND stages.
In-Vitro
Pre-Clinical
Pre-IND
IND
Melanoma
Liver Fibrosis
Lung Fibrosis
Skin Fibrosis
Pancreatic Cancer
Diagnostics
Multiple companies have developed FAK inhibitors that target the kinase domain of FAK, but most have failed in clinical trials due to innate resistance mechanisms.
​
FAKnostics' inhibitor targets the non-kinase domain, which plays important roles in cancer progression and metastasis.
​
Our FAKnosTest® companion diagnostic is based on our proprietary FAK antibody thoroughly tested on thousands of biopsies.
Proof of Concept
Formulation Optimization
Commercial
FAKnosTest CRC Prognostic
Companion Melanoma
Companion Fibrosis
Companion Pancreatic Cancer
